69 filings
Page 2 of 4
8-K
0pd9q
2 Aug 17
Departure of Directors or Certain Officers
12:00am
8-K
mw9gijn cmh5
16 Jun 17
Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing
12:00am
8-K
5ge23 irf0u
4 May 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
llu twjhv
18 Apr 17
Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial
12:00am
8-K
9lkgitx0fnfmi5i
14 Apr 17
Other Events
12:00am
8-K
ui6cf84
4 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
uvnnx
23 Mar 17
Termination of a Material Definitive Agreement
12:00am
8-K
ody0tall
9 Mar 17
Cost Associated with Exit or Disposal Activities
12:00am
8-K
4p0r0d0a4o47mu5k97r4
6 Mar 17
Termination of a Material Definitive Agreement
12:00am
8-K
jnxntxc7mdoi2m
22 Feb 17
Other Events
12:00am
8-K
4kvvsrc z7b7ay1b5
23 Jan 17
Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University
12:00am
8-K
km43j20tcqs1ef
15 Dec 16
Argos Therapeutics Appoints Dr. Ralph Snyderman and Irackly Mtibelishvily to the Company’s Board of Directors
12:00am
8-K
8bd25 m0mzq
14 Nov 16
Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
12:00am
8-K
lp8b thsve4
10 Aug 16
Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
12:00am
8-K
6dfl9b5xkjlcc 2b9c
29 Jul 16
Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants
12:00am
8-K
jicnz39wdkm699g
27 Jul 16
Other Events
12:00am
8-K
mavjyuax oyg2pmryuo
11 Jul 16
Dr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer
12:00am
8-K
bnrh2g fb65uksi5ncuf
29 Jun 16
Other Events
12:00am
8-K
y6awr
13 Jun 16
Departure of Directors or Certain Officers
12:00am
8-K
41t1 flai
12 May 16
Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights
12:00am